# Iteria Biopharma SL

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iteria-biopharma-sl

- Industry: Biotechnology
- Headquarters: A Coruna, Spain
- Website: www.iteriabiopharma.com/
- Total disclosed funding: $5.8M
- Latest round: Seed (Apr 16, 2026)
- Investors on record: 2

## About

Based in A Coruña, Spain, Iteria Biopharma SL specializes in the development of innovative oncology therapies targeting difficult cancer types, focusing on high unmet medical needs.Iteria Biopharma SL is dedicated to the development of advanced therapies for cancer. The company was founded in A Coruña, Spain in 2024, and has executed one deal to date. In April 2026, Iteria Biopharma SL raised EUR 5 million in Seed funding led by Inveready Asset Management, with participation from Xesgalicia. The founder's history and previous ventures are not specified.Iteria Biopharma is focused on the development of first-in-class new chemical entities (NCEs) aimed at modulating difficult targets for the treatment of cancers with high unmet medical needs. Their offerings leverage advanced medicinal chemistry to create precision drugs that address pharmacologically validated oncology targets. The pipeline includes innovative development candidates supported by strong intellectual property protections. The company serves oncology professionals, healthcare providers, and research institutions across international markets, including Europe and North America, enhancing treatment options and improving outcomes in cancer care.Iteria Biopharma generates revenue through strategic partnerships and collaborations within the biotechnology sector, focusing on B2B engagements with healthcare organizations and pharmaceutical companies. Their transaction structure primarily involves licensing agreements and research collaborations, enabling shared expertise in drug development. Revenue is derived from milestone payments linked to the advancement of product candidates through clinical trials and eventual commercialization, emphasizing long-term partnerships and mutual interests with clients and stakeholders in healthcare.In April 2026, Iteria Biopharma SL secured EUR 5 million in Seed funding to advance its preclinical development and initiate a Phase 1 clinical trial for its lead drug targeting metastatic prostate cancer. The funding will also support the progression of early research programs for lung, pancreatic, and colorectal cancers. The company aims to expand its presence into new markets across Europe and North America by 2027.

## Funding rounds

- Seed, Apr 16, 2026, $5.8M — Inveready Asset Management, Xesgalicia

## Investors

- Inveready Asset Management (https://capitalatlas.ai/funds/inveready-asset-management) — Seed
- Xesgalicia (https://capitalatlas.ai/funds/xesgalicia) — Seed